A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
01
06
2018
accepted:
07
06
2018
pubmed:
4
7
2018
medline:
31
5
2019
entrez:
4
7
2018
Statut:
ppublish
Résumé
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R
Identifiants
pubmed: 29967379
doi: 10.1038/s41375-018-0196-8
pii: 10.1038/s41375-018-0196-8
pmc: PMC6326953
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-170Subventions
Organisme : NCI NIH HHS
ID : P01 CA155258
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Genes Chromosomes Cancer. 2005 Jan;42(1):95-106
pubmed: 15472896
Stat Med. 2005 Feb 15;24(3):479-89
pubmed: 15532086
Blood. 2005 Jul 1;106(1):296-303
pubmed: 15755896
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Hematology. 2005;10 Suppl 1:117-26
pubmed: 16188652
Blood. 2006 Sep 1;108(5):1724-32
pubmed: 16705089
Leukemia. 2007 Mar;21(3):582-4
pubmed: 17215851
J Clin Oncol. 2007 Oct 1;25(28):4452-8
pubmed: 17785704
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Br J Haematol. 2009 Nov;147(4):484-94
pubmed: 19744130
Blood. 2010 Oct 14;116(15):e56-65
pubmed: 20616218
Haematologica. 2010 Nov;95(11):1973-6
pubmed: 20634494
J Clin Oncol. 2010 Oct 10;28(29):4473-9
pubmed: 20697090
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Blood. 2012 Jan 5;119(1):7-15
pubmed: 22021371
Blood. 2012 Jun 7;119(23):5374-83
pubmed: 22498739
Blood. 2012 Aug 2;120(5):1077-86
pubmed: 22573403
Nucleic Acids Res. 2013 Jan;41(Database issue):D962-9
pubmed: 23161690
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Leukemia. 2014 Feb;28(2):269-77
pubmed: 23974982
Nat Commun. 2014;5:2997
pubmed: 24429703
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Blood. 2014 Jul 10;124(2):251-8
pubmed: 24829203
Leuk Res. 2014 Jul;38(7):751-5
pubmed: 24836762
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Blood. 2016 Jun 16;127(24):3004-14
pubmed: 26966091
Blood. 2016 Sep 29;128(13):1735-44
pubmed: 27516441
Blood Cancer J. 2017 Feb 24;7(2):e535
pubmed: 28234347
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Haematologica. 2017 Sep;102(9):e364-e367
pubmed: 28550191
Leukemia. 2018 Jan;32(1):102-110
pubmed: 28584253
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2
pubmed: 28886839
Leukemia. 2018 Apr;32(4):971-978
pubmed: 29099494
J Clin Pathol. 2018 Oct;71(10):895-899
pubmed: 29760015
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741